Haemonetics Corporation
$ 78.20
-2.05%
12 Jun - close price
- Market Cap 3,628,407,000 USD
- Current Price $ 78.20
- High / Low $ 80.94 / 77.02
- Stock P/E 38.95
- Book Value 17.60
- EPS 2.05
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.06 %
- ROE 0.12 %
- 52 Week High 87.32
- 52 Week Low 47.32
About
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$81.60
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-05 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-08 | 2023-11-02 | 2023-08-08 |
| Reported EPS | 1.29 | 0.95 | 1.27 | 1.1 | 1.24 | 0.74 | 1.12 | 1.02 | 0.9 | 1.04 | 0.99 | 1.05 |
| Estimated EPS | 1.27 | 0.9 | 1.11 | 1.02 | 1.22 | 0.91 | 1.07 | 1.01 | 0.89 | 0.94 | 0.89 | 0.73 |
| Surprise | 0.02 | 0.05 | 0.16 | 0.08 | 0.02 | -0.17 | 0.05 | 0.01 | 0.01 | 0.1 | 0.1 | 0.32 |
| Surprise Percentage | 1.5748% | 5.5556% | 14.4144% | 7.8431% | 1.6393% | -18.6813% | 4.6729% | 0.9901% | 1.1236% | 10.6383% | 11.236% | 43.8356% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: HAE
2026-06-11 12:39:32
Haemonetics (HAE) is gaining investor attention due to increased interest in the medical device sector and internal restructuring, including merging its Plasma and Blood Center units into a single Apheresis segment. Despite analyst concerns about competition in vascular closure and the need for improved margins, the company's valuation appears modestly undervalued. This reorganization aims to provide clearer insights into management's performance in its core franchises, especially concerning profitability and market strategy.
2026-06-09 20:08:58
This article announces an ARS filing by Haemonetics Corp (HAE) on June 9, 2026, which is categorized with a low filing impact and neutral sentiment. The filing is available as a PDF document through SEC EDGAR. The page also provides an overview of HAE stock, including market capitalization, recent news, and other SEC filings, with links to the company's stock data and further information.
2026-06-09 20:08:58
Haemonetics Corporation (HAE) saw a significant 6.6% increase in its stock price, reaching $79.83, as part of a broader rally across the medical device sector. This surge, which also impacted other medical device companies, suggests a renewed investor interest in the industry rather than being driven by company-specific news for Haemonetics. The article notes that the coordinated sector strength indicates a potential re-evaluation of sector valuations or shifts in macroeconomic factors favoring device manufacturers.
2026-06-09 16:08:58
Haemonetics (HAE) has restructured its business segments into Apheresis and MedSurg, with recent trading showing significant short-term share price returns. The stock is currently trading at $74.88, below an analyst target of $81.60, and is considered 13.8% undervalued with a fair value of $86.90 due to strong earnings quality, innovation in plasma collection, and new software contracts. Investors are encouraged to review company data and consider risks amid enthusiasm for its growth potential.
2026-06-09 03:32:23
Maryanne Maunsell Farris, VP and Chief Accounting Officer of Haemonetics Corp (NYSE: HAE), had 259 shares withheld at $71.28 per share to cover tax obligations related to the vesting of restricted stock units (RSUs). This tax-withholding disposition is a standard procedure and not an open-market sale. After this transaction, Ms. Maunsell Farris beneficially owns 6,242 common shares, which include previously reported unvested RSUs.
2026-06-08 20:39:23
Haemonetics Corp's Senior Vice President of Human Resources, Laurie A. Miller, reported a tax-related disposition of 313 shares. These shares, valued at $71.28 each, were withheld to cover tax obligations upon the vesting of previously granted restricted stock units. Following this transaction, Miller directly holds 40,987 shares, including unvested RSUs.
